Status:
COMPLETED
Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Lead Sponsor:
La Jolla Institute for Immunology
Conditions:
Influenza A
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
Every 1-2 years, the seasonal influenza vaccine composition changes to include updated viruses, yet the precise effects of updating the vaccine remain understudied. Since the vaccine formulation for e...
Eligibility Criteria
Inclusion
- Be between 18-64 years of age
- Males or non-pregnant, non-nursing females
- Weigh at least 85 pounds for whole blood draw
- Ability to provide signed informed consent
- Subjects must plan to receive the intramuscular influenza vaccine at the La Jolla Institute for Immunology
Exclusion
- Received an influenza vaccine in the past year
- Infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
- History of certain anemias
- Presence of significant cardiovascular disease, systemic diseases including, but not limited to, diabetes which is not controlled, renal disease, liver disease, malignancy, infection, or blood clotting disorder
- Inability to provide informed consent
- Recent whole blood donation within 56 days or leukapheresis within 112 days
- Children (under 18 years of age), elderly (65 years of age or older), pregnant or nursing females
- Individuals with egg allergies
- Has ever had Guillain-Barré syndrome
Key Trial Info
Start Date :
May 21 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 6 2025
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06567860
Start Date
May 21 2024
End Date
February 6 2025
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
La Jolla Institute for Immunology
La Jolla, California, United States, 92037